Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Sees 18.5% Sales Rise after Shire Buy, but Braces for Losses in FY2019
Takeda Pharmaceutical saw its consolidated sales grow 18.5% in FY2018 ended March, with Shire’s three-month revenue added following its £46 billion takeover early this year, but the drug giant is bracing for losses in the next fiscal year as acquisition…
To read the full story
Related Article
- Takeda’s FY2019 Revenue Up 57% on Shire Buy, Underlying Growth at 1.6%
May 14, 2020
- Takeda’s April-Dec. Underlying Sales Sag 1.2% as Hemophilia Meds Falter; Outlook Lifted after Buyout Cost Adjustment
February 5, 2020
- Takeda’s Underlying Revenue Skids 0.2% in 1st Half as Rare Disease Biz Weighs
November 1, 2019
- Takeda Squeezes Projected Losses for FY2019 as Velcade Copy Lags
August 1, 2019
- Takeda Cuts FY2018 Profit Outlook on Shire Takeover
April 26, 2019
- Takeda Sees Flat Sales as Brisk US Revenue Offset by Off-Patent Divestiture
November 1, 2018
- Takeda Delivers Double-Digit Profit Growth as Entyvio Nets 200-Plus Billion Yen
May 15, 2018
BUSINESS
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
- Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
- UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
March 3, 2026
- Itochu Snaps Up CoreMed to Bolster Japan Entry Support
March 3, 2026
- Ono to Transfer Opalmon, Prostandin to Daito by November
March 3, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…